Atara Biotherapeutics (NASDAQ:ATRA) Lifted to “Hold” at BidaskClub
Several other equities research analysts have also recently commented on the company. Stifel Nicolaus initiated coverage on Atara Biotherapeutics in a research note on Wednesday, May 22nd. They issued a buy rating and a $41.00 target price for the company. ValuEngine cut Atara Biotherapeutics from a buy rating to a hold rating in a research note on Friday, May 17th. Wedbush reissued an outperform rating on shares of Atara Biotherapeutics in a research note on Wednesday, May 29th. Zacks Investment Research raised Atara Biotherapeutics from a sell rating to a hold rating in a research note on Tuesday, July 16th. Finally, Canaccord Genuity reissued a buy rating and issued a $70.00 target price on shares of Atara Biotherapeutics in a research note on Monday, July 1st. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $36.50.
Shares of NASDAQ ATRA traded up $0.24 during midday trading on Tuesday, hitting $15.82. The stock had a trading volume of 135,336 shares, compared to its average volume of 606,691. The company’s 50-day simple moving average is $13.71 and its 200 day simple moving average is $25.08. The firm has a market cap of $839.70 million, a P/E ratio of -3.00 and a beta of 2.10. Atara Biotherapeutics has a fifty-two week low of $11.89 and a fifty-two week high of $43.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.80 and a quick ratio of 7.80.
In other news, Director Eric Dobmeier purchased 2,000 shares of the business’s stock in a transaction dated Thursday, June 27th. The shares were bought at an average cost of $19.50 per share, for a total transaction of $39,000.00. Following the completion of the acquisition, the director now directly owns 16,000 shares in the company, valued at approximately $312,000. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 7.00% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Maverick Capital Ltd. increased its position in shares of Atara Biotherapeutics by 156.4% in the second quarter. Maverick Capital Ltd. now owns 2,232,476 shares of the biotechnology company’s stock valued at $44,895,000 after acquiring an additional 1,361,712 shares during the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of Atara Biotherapeutics in the second quarter valued at about $266,000. Nuveen Asset Management LLC acquired a new stake in shares of Atara Biotherapeutics in the second quarter valued at about $4,006,000. UBS Asset Management Americas Inc. increased its position in shares of Atara Biotherapeutics by 18.0% in the second quarter. UBS Asset Management Americas Inc. now owns 267,773 shares of the biotechnology company’s stock valued at $5,385,000 after acquiring an additional 40,796 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics in the second quarter valued at about $912,000. Institutional investors own 91.79% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Further Reading: How to use beta for portfolio diversification
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.